Table 2.
Examples of FDA approved monoclonal antibodies
| Generic name | Target | Type | Indication |
| Rituximab | CD20 | Chimeric IgG1 | Non-Hodgkins lymphomas |
| Trastuzumab | HER-2/neu | Humanized IgG1 | Breast cancer |
| Alemtuzumab | CD52 | Humanized IgG1 | Chronic lymphaocytic leukaemia |
| Bevacizumab | VEGF | Humanized IgG1 | Colorectal cancer |
| Non-small cell lung cancer | |||
| Breast cancer | |||
| Glioblastoma | |||
| Renal cancer | |||
| Cetuximab | EGFR | Chimeric IgG1 | Colorectal cancer |
| Head and neck cancer | |||
| Panitumumab | EGFR | Human IgG1 | Colorectal cancer |
| Ofatumumab | CD20 | Human IgG1 | Chronic lymphocytic leukaemia |
| Gemtuzumab Ozogamicin | CD33 | Humanized IgG4 conjugated to calicheamicin | Acute myeloid leukaemia |
| 90Y-Ibritumomab Tiuxetan | CD20 | 90Y-radiolabeled murine IgG1 | Non-Hodgkins lymphoma |
| 131I-Tositumomab | CD20 | 131I-radiolabeled murine IgG2a | Non-Hodgkins lymphoma |
FDA: Food and Drug Administration; EGFR: Epidermal growth factor receptor; VEGF: Vascular endothelial growth factor.